Literature DB >> 12677257

The Role of PPARs in the Transcriptional Control of Cellular Processes.

Youfei Guan, Yahua Zhang, Matthew D. Breyer.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are transcription factors that belong to the nuclear hormone receptor superfamily. PPAR has three isoforms designated PPARalpha, PPARbeta/delta and PPARgamma. Although all three isoforms share similar protein sequence and structure, they differ in tissue distribution, ligand selectivity and biological actions. As ligand-activated transcription factors, PPARs participate in a broad spectrum of biological processes, including cell differentiation, energy balance, lipid metabolism, insulin sensitivity, bone formation, inflammation and tissue remodeling. PPARalpha is the molecular target of the hypolipidemic fibrates including benzafibrate and clofibrate. In general, PPARalpha is expressed in tissues with high mitochondrial and beta-oxidation activity corresponding to its role in regulating lipid metabolism. In contrast, PPARbeta/delta is ubiquitously expressed and has been suggested to be involved in bone formation, oocyte implantation and lipid catabolism. PPARbeta/delta ligands have been found to effectively improve lipid profile and insulin resistance. PPARgamma is a key player in adipogenesis and plays an important role in diverse cellular processes such as cell cycle regulation, cell differentiation and insulin sensitivity. Synthetic PPARgamma ligands, including thiazolidinediones and non-thiazolidinedione compounds, have been shown to increase insulin sensitivity and improve hyperglycemia in insulin resistance and noninsulin dependent diabetes mellitus. The biological effects of PPARs indicate that both agonists and antagonists for PPARs may provide new therapeutic options in a variety of human diseases. (c) 2002 Prous Science. All rights reserved.

Entities:  

Year:  2002        PMID: 12677257     DOI: 10.1358/dnp.2002.15.3.840011

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  19 in total

1.  Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer.

Authors:  M Crous-Bou; G Rennert; R Salazar; F Rodriguez-Moranta; H S Rennert; F Lejbkowicz; L Kopelovich; S M Lipkin; S B Gruber; V Moreno
Journal:  Mutagenesis       Date:  2012-03       Impact factor: 3.000

2.  Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.

Authors:  Andrew Sauerbeck; Jianxin Gao; Ryan Readnower; Mei Liu; James R Pauly; Guoying Bing; Patrick G Sullivan
Journal:  Exp Neurol       Date:  2010-10-20       Impact factor: 5.330

3.  Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease.

Authors:  L Hunter Randy; Bing Guoying
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

4.  Ang II induce kidney damage by recruiting inflammatory cells and up regulates PPAR gamma and Renin 1 gene: effect of β carotene on chronic renal damage.

Authors:  Gopal Kaliappan; P Nagarajan; Ramya Moorthy; S Kalai Gana Selvi; T Avinash Raj; Jerald Mahesh Kumar
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

5.  Conditional deletion of cardiomyocyte peroxisome proliferator-activated receptor γ enhances myocardial ischemia-reperfusion injury in mice.

Authors:  Michael J Hobson; Paul W Hake; Michael O'Connor; Christine Schulte; Victoria Moore; Jeanne M James; Giovanna Piraino; Basilia Zingarelli
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

6.  Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells.

Authors:  Yumin Chen; Qiong Luo; Zibo Xiong; Wei Liang; Li Chen; Zuying Xiong
Journal:  Int J Clin Exp Pathol       Date:  2012-07-17

7.  PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.

Authors:  Jee-Young Han; Ye-Ji Kim; Lucia Kim; Suk-Jin Choi; In-Suh Park; Joon-Mee Kim; Young Chae Chu; Dae-Ryong Cha
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

Review 8.  Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Authors:  Francisco A Monsalve; Radha D Pyarasani; Fernando Delgado-Lopez; Rodrigo Moore-Carrasco
Journal:  Mediators Inflamm       Date:  2013-05-27       Impact factor: 4.711

9.  The Functions of PPARs in Aging and Longevity.

Authors:  Adnan Erol
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

10.  Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.

Authors:  Catharine Whiteside; Hong Wang; Ling Xia; Snezana Munk; Howard J Goldberg; I George Fantus
Journal:  Exp Diabetes Res       Date:  2009-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.